Global Protein Therapeutics Market Size Study & Forecast, by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), By Application (Metabolic Disorders, Immunologic Disorde

Global Protein Therapeutics Market Size Study & Forecast, by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), By Application (Metabolic Disorders, Immunologic Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Others), and Regional Analysis, 2023-2030

Global Protein Therapeutics Market is valued at approximately USD 325.35 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 7.1% over the forecast period 2023-2030. Protein therapeutics refers to a class of therapeutic agents that are based on proteins or peptides. Proteins are substantial molecules that are crucial for a variety of biological functions, such as immune function, metabolism, and cell signaling. These therapeutic compounds are intended to treat illnesses, disorders, or medical conditions by interacting with certain bodily targets, such as receptors, enzymes, or signaling molecules. The favorable regulatory environment, increase in the geriatric population, and development of the biologics sector, coupled with the rise in healthcare expenditure are the key factors that are spurring the market demand across the globe.

Additionally, the rising prevalence of chronic diseases, such as cancer, diabetes, cardiovascular disorders, and autoimmune diseases is propelling the demand for protein therapeutics during the estimated period. According to National Cancer Institute, in 2018, the number of cancer patients is estimated to account for 18.1 million, which is projected to reach 29.5 million patients by the year 2040. Moreover, the International Diabetic Federation (IDF) reported that in 2021 approximately 537 million adults (20-79 years) are living with diabetes. Also, the total number of people living with diabetes is expected to increase to 643 million by 2030 and 783 million by 2045. Thus, these conditions generally require targeted and personalized treatment approaches like protein therapeutics, which, in turn, augment the market growth at a considerable rate. Furthermore, the rising advancements in biotechnology and protein engineering, as well as the growth in proteomic research present various lucrative opportunities over the forecasting years. However, the high production costs required and the complex manufacturing processes are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Protein Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing advancements in biotechnology, growing funding for research and development activities, along with the presence of key players in the region. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecasting years. The rapidly growing geriatric population, increasing patient awareness toward protein therapeutics, as well as rising prevalence of chronic diseases are significantly propelling the market demand across the region.

Major market players included in this report are:
Novo Nordisk AS
Baxter International Inc.
Amgen Inc.
Merck and Co., Inc.
Sanofi S.A.
Eli Lilly And Company
Abbott Laboratories
Pfizer Inc.
Johnson and Johnson (Janssen Pharmaceuticals)
F. Hoffmann La Roche Ltd

Recent Developments in the Market:
In December 2022, Enlaza Therapeutics announced the introduction with USD 61 million in financing with the objective of advancing the company’s first covalent biologic therapeutic platform. The company integrated novel innovations that allow the introduction of proprietary unnatural amino acids to protein drugs, which allows specific covalent binding to their target proteins.

Global Protein Therapeutics Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Application, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Monoclonal Antibodies
Insulin
Fusion Protein
Erythropoietin
Interferon
Human Growth Hormone
Follicle Stimulating Hormone

By Application:
Metabolic Disorders
Immunologic Disorders
Cancer
Hormonal Disorders
Genetic Disorders
Others
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Novo Nordisk AS
Baxter International Inc.
Amgen Inc.
Merck and Co., Inc.
Sanofi S.A.
Eli Lilly And Company
Abbott Laboratories
Pfizer Inc.
Johnson and Johnson (Janssen Pharmaceuticals)
F. Hoffmann La Roche Ltd

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.